Mark Cobbold

Mark Cobbold is a prominent figure in the field of oncology and immunotherapy, currently serving as the VP of Oncology Early Discovery at AstraZeneca, a position he has held since September 2019.1 With over 500 connections on LinkedIn, Cobbold is based in the Greater Boston Area.1

Professional Experience

Cobbold's career is marked by significant contributions to both academia and industry:

Industry Roles::

• VP Oncology Early Discovery at AstraZeneca (September 2019 - Present)1
• Scientific Co-Founder of multiple biotech companies, including:
  • GigaMune (January 2019 - Present)
  • Gritstone Oncology (October 2015 - Present)
  • Revitope (November 2014 - Present)
  • PhosImmune, Inc. (September 2012 - June 2015)
  • Serascience (May 2011 - June 2015)1

Academic Positions::

• Associate Member at the Broad Institute (September 2015 - September 2019)
• Associate Professor at Massachusetts General Hospital (June 2015 - September 2019)
• Associate Professor of Medicine at Harvard University (June 2015 - September 2019)
• Reader in Translational Immunology at the University of Birmingham (March 2014 - May 2015)1

Research Focus

Cobbold's work primarily revolves around immuno-oncology (IO) and cell therapy research:

• He is actively involved in advancing cancer medicines through collaboration and knowledge sharing.3
• Cobbold has been instrumental in AstraZeneca's efforts to harness the benefits of cell therapies for solid tumors.4
• He has highlighted the company's immuno-oncology research at conferences like SITC (Society for Immunotherapy of Cancer).5

Education

Cobbold holds a PhD in Immunology/Immunotherapy from the University of Birmingham, which he completed between 2000 and 2003.1

Thought Leadership

As a thought leader in his field, Cobbold regularly shares insights on:

• The complexities of the immune system and how cancer can hijack it2
• The future of immunotherapy in oncology7
• The role of immuno-oncology and cell therapy in cancer treatment6

Through his work at AstraZeneca and his contributions to various biotech startups, Mark Cobbold continues to play a significant role in shaping the future of cancer treatment, particularly in the areas of immuno-oncology and cell therapy.